Translate Autumn - Winter 2016/2017 | Page 9

Spotlight: The people behind ISTM I am Dr Clare Hoskins, Lead of the Nanopharmaceutics Research Group. I was appointed as Lecturer in Pharmaceutics at Keele University in 2011 with subsequent promotion to Senior Lecturer in 2016. I completed my PhD in polymers for drug delivery at the Robert Gordon University in Aberdeen. Following this I was appointed to a postdoctoral position at the University of Dundee, to investigate the use of metallic nanoparticles for application in nerve regeneration. My research interests at Keele concern the design and fabrication of novel image guided drug delivery sys- tems. I am a member of the Royal Society of Chemistry (RSC); the United Kingdom & Ireland Controlled Release Society (UKICRS); and the British Society for Nanomedicine and the Controlled Release Society (CRS). I sit as a Committee Member of the CRS Preclinical Sciences and Animal Health Committee and am currently the elected Secretary of the RSC Chemical Nanosciences and Nanotechnology Network. I serve as an editorial board member for the Journal of Nanomedicine Research and recently was invited to Chair the 6th Global Experts Meeting on Nanotechnology and Nanomaterials conference. Moving forward I am hoping to keep up this success and help develop Keele University as a centre of excellence for Nanopharmaceutics. I am Dr Tony Curtis and I work as a Senior Lecturer in Organic and Medicinal Chemistry at Keele University. I joined Keele in 1993 as Lecturer in Organic Chemistry in the Department of Chemistry and was one of the key figures in setting up the School of Pharmacy within the Faculty of Medicine and Health Sciences. I obtained my PhD in anticancer drug synthesis from Manchester University and subsequently was appointed to a postdoctoral position in Boston College, Massachussetts where I made simple enzyme mimics. I carry out my research into synthetic chemistry, drug discovery and delivery as part of the Keele Nanopharmaceutics research group. Recently I was awarded the Institute of Science and Technology in Medicine Research Fellowship, which allowed me to dedicate more time to research in the laboratory and to help raise my profile in the field. I am a Fellow of the Royal Society of Chemistry, and member of the American Chemical Society; Association for Pharmaceutical Science; Controlled Release Society (CRS); United Kingdom & Ireland Controlled Release Society (UKICRS); British Society for Nanomedicine; and the British Association for Cancer Research. NANOPHARMACEUTICS 8